TY  - GEN
AU  - van de Putte,L B A
AU  - Rau,R
AU  - Breedveld,F C
AU  - Kalden,J R
AU  - Malaise,M G
AU  - van Riel,P L C M
AU  - Schattenkirchner,M
AU  - Emery,P
AU  - Burmester,G R
AU  - Zeidler,H
AU  - Moutsopoulos,H M
AU  - Beck,K
AU  - Kupper,H
TI  - Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
SN  - 0003-4967
PY  - 2004///0126
KW  - Adalimumab
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Antibodies, Monoclonal, Humanized
KW  - Antirheumatic Agents
KW  - Arthritis, Rheumatoid
KW  - drug therapy
KW  - Double-Blind Method
KW  - Drug Resistance
KW  - Female
KW  - Humans
KW  - Injections, Subcutaneous
KW  - Male
KW  - Middle Aged
KW  - Treatment Outcome
KW  - Tumor Necrosis Factor-alpha
KW  - antagonists & inhibitors
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1136/ard.2003.009563
ER  -